Mehdi Benamar- Institute of Regenerative Medicine and Biotherapy, INSERM, University of Montpellier, Montpellier, France
Editorial on the Research Topic
The transcriptional and metabolic role of Foxp3 in regulatory T cells
Inflammation is an indispensable feature of immune defense, yet when unchecked it becomes a driving force behind chronic disease, autoimmunity, and tissue destruction (1, 2). The immune system therefore requires dedicated mechanisms to restrain excessive responses while preserving protective immunity. At the center of this delicate immunological balance reside regulatory T cells (Tregs), a specialized lineage of CD4 T cells defined by expression of the transcription factor FOXP3, a member of the forkhead family of transcription factors (3–7). Early insights into FOXP3 established its necessity for Treg lineage commitment and stability (5, 8), with mutations in FOXP3 resulting in profound immune dysregulation and multi-organ autoimmunity (9). But beyond lineage specification, FOXP3 actively shapes the Treg transcriptome, collaborating with co-factors and chromatin regulators to fine-tune gene expression in a context-dependent manner (10–13). This flexible chromatin engagement allows Tregs to occupy distinct functional states, enabling suppression, tissue repair, and even metabolic regulation in response to local demands. Over the past 30 years, advancements in Treg biology have profoundly reshaped our understanding of immune homeostasis, revealing not merely suppressors of inflammation, but dynamic orchestrators of immunological tolerance and tissue integrity. Tregs employ a multifaceted repertoire of mechanisms to restrain pathological immune responses. These include secretion of anti-inflammatory cytokines such as IL-10, IL-35 and TGF-β, modulation of antigen-presenting cell function, metabolic competition for IL-2, and direct cell contact-dependent suppression (14). They communicate with cells of both innate and adaptive immunity, tempering effector responses while preserving capacity for protective host defense. Importantly, the phenotypic and functional heterogeneity within Treg populations, shaped by tissue-specific cues and molecular signatures, has emerged as a critical determinant of their regulatory capacity in distinct inflammatory environment (15–21). Treg cells subsets distinguished by transcriptional programs, surface markers, and tissue residency profiles can exert specialized roles in contexts ranging from mucosal tolerance to systemic autoimmune regulation (16). This heterogeneity presents both an intellectual challenge and an extraordinary therapeutic opportunity: understanding how distinct Treg subsets develop, navigate inflamed tissues, and reprogram local immune networks promises new avenues for precision immunotherapy.
Central to this remarkable functional repertoire is FOXP3 whose sustained expression defines Treg identity and function. Concurrent with its transcriptional influence, Foxp3 orchestrates metabolic programs that are essential to Treg function and resilience. Unlike conventional effector T cells that rely heavily on glycolysis to fuel rapid proliferation, Tregs preferentially engage oxidative phosphorylation (OXPHOS) and fatty acid oxidation, metabolic pathways that support their suppressive capacity and long-term survival (22). Foxp3 actively represses glycolytic genes while promoting mitochondrial fitness, enabling Tregs to maintain function even in nutrient-challenged or inflammatory environments such as tumors, ischemic tissues, or inflamed mucosa (22). This metabolic specialization is not merely a correlate of identity but a mechanistic pillar of Treg action: dysregulated metabolism compromises suppressive function and can precipitate inflammatory disease. The metabolic landscape encountered by Tregs varies widely across tissues. Tregs resident in these niches not only withstand low-glucose and high-lactate conditions but can exploit these environments through Foxp3-dependent metabolic reprogramming. By suppressing glycolysis and enhancing OXPHOS, Foxp3 equips Tregs with a metabolic edge in hostile microenvironments, a feature that likely contributes to their dominant role in tissue homeostasis and regulation (23, 24).
This Research Topic brings together a rich collection of articles that illuminate the transcriptional and metabolic dimensions of Foxp3 biology. From mechanistic perspectives on how Foxp3 collaborates with transcriptional networks to emerging insights into metabolic heterogeneity and flexibility. Articles delve into how alternative splicing of Foxp3 impacts metabolic pathways, how Foxp3 partner proteins modify Treg fate and function, and how metabolic cues intersect with epigenetics to influence immune outcomes in autoimmunity, infection, and cancer. In summary, Foxp3 sits at a strategic crossroads, linking the transcriptional architecture of Tregs with their metabolic phenotype. Deciphering this linkage is not only of fundamental scientific interest but also of profound clinical importance in diseases where immune balance is lost. The work showcased in this Research Topic represents a significant stride toward that understanding, and promises to catalyze new discoveries at the intersection of gene regulation and immunometabolism. Indeed, harnessing Tregs as therapeutic agents represents one of modern immunology’s most exciting frontiers. Early clinical trials have demonstrated the safety of Treg cell therapies, and ongoing studies are increasingly focused on efficacy, stability, and precision targeting. Genetically engineered Tregs, tailored for enhanced suppressive activity or directed to specific inflammatory antigens, hold particular promise for conditions where conventional treatments fall short. Looking forward, the challenge is to translate our expanding molecular and cellular insights into interventions that safely and effectively restore immune equilibrium. Finally, this Research Topic highlights not only how far the field has come, but also how much remains to be discovered. By continuing to unravel their complexity, we take critical steps toward therapies that could transform the management of inflammatory disease across broad therapeutic landscapes. Looking ahead, the integration of single-cell genomics, spatial transcriptomics, and metabolic profiling promises to deepen our understanding of how Foxp3 shapes Treg identity in situ. Such high-resolution insights will be essential to design precision therapies that calibrate immune regulation with minimal off-target effects.
Author contributions
MB: Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Georgiev P, Benamar M, Han S, Haigis MC, Sharpe AH, and Chatila TA. Regulatory T cells in dominant immunologic tolerance. J Allergy Clin Immunol. (2024) 153:28–41. doi: 10.1016/j.jaci.2023.09.025
2. Sakaguchi S, Yamaguchi T, Nomura T, and Ono M. Regulatory T cells and immune tolerance. Cell. (2008) 133:775–87. doi: 10.1016/j.cell.2008.05.009
3. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. (2001) 27:20–1. doi: 10.1038/83713
4. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. (2001) 27:68–73. doi: 10.1038/83784
5. Fontenot JD, Gavin MA, and Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. (2003) 4:330–6. doi: 10.1038/ni904
6. Khattri R, Cox T, Yasayko SA, and Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. (2003) 4:337–42. doi: 10.1038/ni909
7. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. (2000) 106:R75–81. doi: 10.1172/JCI11679
8. Hori S, Nomura T, and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. (2003) 299:1057–61. doi: 10.1126/science.1079490
9. Georgiev P, Charbonnier LM, and Chatila TA. Regulatory T cells: the many faces of foxp3. J Clin Immunol. (2019) 39:623–40. doi: 10.1007/s10875-019-00684-7
10. Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol. (2012) 13:1010–9. doi: 10.1038/ni.2402
11. Kwon HK, Chen HM, Mathis D, and Benoist C. Different molecular complexes that mediate transcriptional induction and repression by FoxP3. Nat Immunol. (2017) 18:1238–48. doi: 10.1038/ni.3835
12. Hori S and Murakami R. The adaptability of regulatory T cells and Foxp3. Int Immunol. (2021) 33:803–7. doi: 10.1093/intimm/dxab045
13. He M, Zong X, Xu B, Qi W, Huang W, Djekidel MN, et al. Dynamic Foxp3-chromatin interaction controls tunable Treg cell function. J Exp Med. 221:e20232068. doi: 10.1084/jem.20232068
14. Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, and Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol. (2013) 13:461–7. doi: 10.1038/nri3464
15. Burton OT, Bricard O, Tareen S, Gergelits V, Andrews S, Biggins L, et al. The tissue-resident regulatory T cell pool is shaped by transient multi-tissue migration and a conserved residency program. Immunity. (2024) 57:1586–602 e10. doi: 10.1016/j.immuni.2024.05.023
16. Munoz-Rojas AR and Mathis D. Tissue regulatory T cells: regulatory chameleons. Nat Rev Immunol. (2021) 21:597–611. doi: 10.1038/s41577-021-00519-w
17. Harb H, Stephen-Victor E, Crestani E, Benamar M, Massoud A, Cui Y, et al. A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma. Nat Immunol. (2020) 21:1359–70. doi: 10.1038/s41590-020-0777-3
18. Harb H, Benamar M, Lai PS, Contini P, Griffith JW, Crestani E, et al. Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. Immunity. (2021) 54:1186–99 e7. doi: 10.1016/j.immuni.2021.04.002
19. Benamar M, Harb H, Chen Q, Wang M, Chan TMF, Fong J, et al. A common IL-4 receptor variant promotes asthma severity via a Treg cell GRB2-IL-6-Notch4 circuit. Allergy. (2022) 77:3377–87. doi: 10.1111/all.15444
20. Benamar M, Chen Q, Chou J, Jule AM, Boudra R, Contini P, et al. The Notch1/CD22 signaling axis disrupts Treg function in SARS-CoV-2-associated multisystem inflammatory syndrome in children. J Clin Invest. (2023) 133:e163235. doi: 10.1172/JCI163235
21. Benamar M, Contini P, Schmitz-Abe K, Lanzetta O, Getachew F, Bachelin C, et al. Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis. Immunity. (2025) 58:2753–68.e6. doi: 10.1093/jimmun/vkaf283.012
22. de Candia P, Procaccini C, Russo C, Lepore MT, and Matarese G. Regulatory T cells as metabolic sensors. Immunity. (2022) 55:1981–92. doi: 10.1016/j.immuni.2022.10.006
23. Ma S, Ming Y, Wu J, and Cui G. Cellular metabolism regulates the differentiation and function of T-cell subsets. Cell Mol Immunol. (2024) 21:419–35. doi: 10.1038/s41423-024-01148-8
Keywords: autoimmunity, chronic inflammation, FOXP3, regulatory T (Treg) cell, Treg cells metabolism
Citation: Benamar M (2026) Editorial: The transcriptional and metabolic role of Foxp3 in regulatory T cells. Front. Immunol. 17:1796661. doi: 10.3389/fimmu.2026.1796661
Received: 26 January 2026; Accepted: 02 February 2026;
Published: 11 February 2026.
Edited and reviewed by:
Mariolina Salio, Immunocore, United KingdomCopyright © 2026 Benamar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mehdi Benamar, bWVoZGliZW5hbWFyMUBnbWFpbC5jb20=